CLINICAL & PIPELINE·Drug Approval
Generic Rasagiline Mesylate Approval by ALKEM LABS LTD Bolsters Parkinson's Treatment Market
ALKEM LABS LTD secured FDA approval for its generic Rasagiline Mesylate (ANDA201889) in 0.5mg and 1mg oral tablets, manufactured by Ascend Laboratories, LLC and NorthStar RxLLC. This 2017 approval, with subsequent labeling updates, significantly enhances market competition for Parkinson's disease treatment. Procurement and regulatory teams should note the expanded supply options and potential pricing shifts.
90-Day Activity